Health Care

The “Medicare-for-all” plan would cost an estimated $32.6 trillion over the course of 10 years, according to a study.

The “Medicare-for-all” plan introduced by House Democrats will wipe out all the private plans most Americans get their healthcare, according to Rep. Kevin Brady.

A top investor of Bristol-Myers is opposing the Celgene acquisition.

Hyundai and Kia are recalling more than a half million vehicles in the U.S. due to new problems that can cause engine fires.

The bill's sponsors have yet to put forward cost estimates.

In her more than two terms as a U.S. senator representing Minnesota, Amy Klobuchar has built a reputation as an effective champion for consumer safety, sponsoring bills that improve swimming pool safety, ban lead in children's products and tackle the nation's opioid crisis.

Contrary to calls from top Dems, getting able-bodied adults off welfare quickly is the best thing for them.

More than a hundred House Democrats are pushing for a bill to expand Medicare coverage.

More than 1,900 lawsuits have popped up over the past three months alone.

The University of Missouri is suing a pharmacy professor at its Kansas City campus over allegations he stole and sold a student's research, claiming that the school is the rightful owner of the work it believes could be used to make a billion-dollar drug.

The promise of completely ‘free’ medical care of every sort imaginable should sound too good to be true. (Because it is.)

The bill has more than 100 Democratic supporters in the House.

The problem is -- and we are not kidding -- if you confiscated every dime earned by every person in this country, it would not pay for these agendas.

The stock market shook off an early slump and was mixed in morning trading Tuesday as investors weighed conflicting reports on how the U.S. economy is doing.

The Biotechnology Innovation Organization CEO and former Congressman says drug prices can be lowered by reforming the rebate program.

Tuesday's hearing will likely not be the last congressional appearance by drug executives.

The executives will represent companies with some of the highest-grossing drugs in the world, and have routinely raised prices on many of their products.

Collectively, the executives earned more than $63 million in 2017 while raising the prices on many of their popular drugs.

The deal comes as big pharma rushes to get in on burgeoning gene therapy treatments.